Skip to content

Study · Measured the body's own peptide · 2019

4 results

Evaluation of plasma antimicrobial peptide LL-37 and nuclear factor-kappaB levels in stable chronic obstructive pulmonary disease.

Uysal P, Simsek G, Durmus S, Sozer V, Aksan H, Yurt S, Cuhadaroglu C, Kosar F, Gelisgen R, Uzun H

International journal of chronic obstructive pulmonary disease25 Jan 2019Cited by 21 (Europe PMC)

PMID30774329 (opens in a new tab)PMCIDPMC6354692 (opens in a new tab)DOI10.2147/copd.s185602 (opens in a new tab)PepBankPUB-30774329
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with stable COPD, plasma LL‑37 levels were significantly lower than in control subjects.

    In plain wordsIn people with stable COPD, the body's own LL‑37 level in blood was lower than in control subjects.

    Peptide
    LL-37
    Outcome
    DecreasePlasma LL-37 in COPD versus controls
    Study

    n = 171

    Comparator
    Control subjects
    Outcome group
    Immune response · Respiratory

    Source sentences

    Summary
    Plasma LL-37 levels were significantly lower while plasma NF-κB levels of the COPD patients were significantly higher than those of the control subjects (P<0.001, both).
    1 context sentence
    Summary · context
    One hundred and thirty-eight stable COPD patients and 33 control subjects were enrolled in the study.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In patients with stable COPD, plasma LL‑37 levels were significantly lower in group IV than in groups I, II and III.

    In plain wordsIn people with COPD, the body's own LL‑37 level was lowest in the most severe group.

    Peptide
    LL-37
    Outcome
    DecreasePlasma LL-37 by COPD severity group
    Study

    n: not reported in source

    Comparator
    COPD groups I, II and III
    Outcome group
    Immune response · Respiratory

    Source sentences

    Summary
    LL-37 levels were significantly lower in group IV than in groups I, II, and III (P<0.01, all).
    1 context sentence
    Summary · context
    One hundred and thirty-eight stable COPD patients and 33 control subjects were enrolled in the study.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In patients with COPD in high-risk groups C and D, plasma LL‑37 correlated inversely with NF-kB.

    In plain wordsIn people with higher-risk COPD, lower natural LL‑37 levels were linked to higher NF-kB levels.

    Peptide
    LL-37
    Outcome
    Not applicableCorrelation of plasma LL-37 with NF-kB
    Study

    n: not reported in source

    Outcome group
    Immune response · Respiratory

    Measurements

    r
    −0.566
    group C
    r
    −0.694
    group D
    r
    −0.593
    groups C+D combined

    Source sentences

    Summary
    Furthermore, there was an inverse correlation between LL-37 and NF-κB in both the groups C (r=-0.566, Pr=-0.694, Pr=-0.593, P<0.001).
    1 context sentence
    Summary · context
    One hundred and thirty-eight stable COPD patients and 33 control subjects were enrolled in the study.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    In patients with COPD in group C, plasma LL‑37 correlated positively with FEV1.

    In plain wordsIn people with COPD in group C, higher natural LL‑37 levels were linked to better lung function.

    Peptide
    LL-37
    Outcome
    Not applicableCorrelation of plasma LL-37 with FEV1 in group C
    Study

    n: not reported in source

    Outcome group
    Immune response · Respiratory

    Measurements

    r
    0.633
    group C

    Source sentences

    Summary
    Furthermore, in group C, LL-37 and FEV1 were positively correlated (r=0.633, P<0.001).
    1 context sentence
    Summary · context
    One hundred and thirty-eight stable COPD patients and 33 control subjects were enrolled in the study.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:57 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.